SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ISCO

International Stem Cell CORP (ISCO)

United States · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.16+$0.00 (+0.00%)
 
Market cap
$1.28M
Insider Score
Market Cap$1.28M+6.7%
Revenue (ttm)$9.51M
Net Income-$582.00K
EPS-$0.08
Shares Out8.00M
PE Ration/a
Forward PE-0.18
Dividendn/a
Ex-Dividend Daten/a
Volume24,996
Open$0.14
Previous Close$0.16
Day's Range$0.14 - $0.14
52-Week Range$0.12 - $0.54
Beta0.09
Analystsnone
Price Targetn/a
Earnings Daten/a
No price history available.

About ISCO

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It serves professional and retail customers. The company was founded in 2001 and is headquartered in San Diego, California.

Address
9745 Businesspark Avenue, San Diego, CA, 92131, United States
Market Cap
1 million
Employees
33
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$10.50K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+0.00%
5 Days
-5.88%
1 Month
-42.86%
6 Months
-11.11%
1 Year
+6.67%

$ISCO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ISCO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ISCO's directors and management

Net Shares Purchased by Insiders−40k−20k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ISCO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ISCO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ISCO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ISCO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 16
0255075100Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 45.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 16Sep 25Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.